CHI3L1 and cancer: Specifically, the anti-vascular efficacy of mAY in animal xenografts suggests a new and exciting therapeutic avenue whereby a humanized anti-YKL-40 antibody could offer a substantial benefit for the treatment of several cancers, resulting in an enhanced quality of life for patients.